Fast track your newest drug compound or nucleic acid target to the clinic by working with RALA to enhance in vitro and subsequent in vivo performance  

Formulate your original lead compound into a bioavailable drug delivery system. With proven cellular entry, move quickly to valuable research, leading to more informed in vivo studies

Eliminate issues with nucleic acid size and associated scalability of your drug formulation.​ pHion's RALA system is not restricted by the size of your intended cargo, or in the scaling-up of manufacture of your final compound

Get the most out of your compound by increasing the bioavailability profile. pHion's RALA drug delivery system is the first system with an ability to concentrate nucleic acids and other anionic compounds into cells in a non-toxic manner due to the presence of natural amino acids

Increase the therapeutic potential of your nucleic acid vaccine by partnering with pHion and taking advantage of all the benefits of the RALA nanoparticle system

Increase the viral titre of your AAV production through the use of RALA-V, an optimised RALA nanoparticle system for the creation of AAV particles